Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Oncolytics Collaborators Present Preclinical Research on Liver Cancer

Published: Tuesday, April 15, 2014
Last Updated: Tuesday, April 15, 2014
Bookmark and Share
Dr. Adel Jebar has presented a poster at the 8th Annual International Conference on Oncolytic Virus in UK.

Oncolytics Biotech Inc. has announced that Dr. Adel Jebar of the Leeds Institute of Cancer and Pathology, University of Leeds, presented a poster at the 8th Annual International Conference on Oncolytic Virus Therapeutics held in Oxford, UK.

The poster, titled "Combined anti-viral and anti-tumour therapy for virus-associated liver cancer," covered preclinical research into the treatment of hepatocellular carcinoma (HCC) associated with infection by Hepatitis B (HBV) and Hepatitis C (HCV).

Researchers examined REOLYSIN® in panels of both normal and malignant liver cells and administered either REOLYSIN® or saline to SCID mice with HCV-positive HCC xenografts.

The aims of the study were to assess interferon secretion in normal and malignant liver cells in response to reovirus infection; the effects of reovirus infection in normal and malignant liver cells on HBV and HCV proteins; and the anti-viral and anti-cancer effects of reovirus in vivo.

The study results showed that reovirus infection of primary human liver cells and HCC lines induced a robust type I interferon response; that reovirus-conditioned media (filtered to remove reovirus) from both primary human liver cells and JHH1 cells potently inhibits HCV and HBV in vitro with these effects abrogated by the blockade of the type I interferon receptor and soluble interferon beta; and that reovirus inhibits HCC xenograft growth and HCV replication in vivo.

The researchers concluded that the results described a novel dual anti-viral and anti-cancer mechanism for reovirus in HBV/HCV-positive HCC and that reovirus treatment of patients with HBV/HCV positive HCC will likely lead to the suppression, rather than exacerbation, of the underlying oncogenic viral infection. Based on these results, the investigators are evaluating the conduct of a translation clinical study.

"Current clinical practice separates the treatment of viral hepatitis and HCC," said Dr. Matt Coffey, COO of Oncolytics. "The goal of a translational study would be to determine if a combined anti-viral, anti-tumour approach might lead to improved HCC clinical outcomes and the potential for reovirus to be used in the treatment of patients with HBC/HCV but not cancer. The natural induction of interferon likely has far reaching clinical implications in how the virus is exerting anti-tumor as well as anti-viral effects."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Oncolytics Announces First Patients Treated in Phase 1b Study
Study of pembrolizumab in combination with REOLYSIN® and chemotherapy in advanced pancreatic cancer patients.
Thursday, January 21, 2016
Oncolytics Collaborators Present at UK Oncolytic Virus Conference
Collaborators present translational brain cancer clinical data and immunomodulatory preclinical research.
Tuesday, April 15, 2014
Oncolytics Collaborators to Present Preclinical Research in Multiple Myeloma and Melanoma
Research collaborators will make two poster presentations at the AACR 2014 Annual Meeting.
Tuesday, April 08, 2014
Oncolytics Biotech® Announces Third Quarter 2013 Results
Company announces its financial results and operational highlights.
Monday, November 11, 2013
Oncolytics Biotech® Announces Addition to Senior Management Team
Appointment of Dr. Jeremy Grushcow to the role of General Counsel.
Monday, September 16, 2013
Oncolytics Announces Positive Final Tumour Response Data for U.S. Phase 2 Study of REOLYSIN®
Final progression-free survival and safety data for the study will be reported later in 2013.
Tuesday, September 10, 2013
Oncolytics Meets Primary Endpoint in U.S. Phase 2 Study of REOLYSIN®
Company has met primary overall statistical endpoint in U.S. Phase 2 clinical trial in SCCLC patients.
Tuesday, May 28, 2013
Oncolytics Meets Primary Endpoint for First Stage of U.S. Phase 2 Metastatic Melanoma Trial
Company announces preliminary results from trial in patients using intravenous administration of REOLYSIN®.
Monday, May 27, 2013
Oncolytics Announces 2012 Year End Results
Company has completed two financings over the last 14 months raising gross proceeds in excess of $50 million.
Tuesday, March 19, 2013
Oncolytics Completes Patient Enrollment in U.S. Phase II Clinical Trial
Investigating REOLYSIN® in combination with gemcitabine in patients with advanced or metastatic pancreatic cancer.
Thursday, February 21, 2013
Oncolytics Announces Additional Positive REOLYSIN® Clinical Trial Data from Phase 2 Study
Study enroll patients with metastatic or recurrent squamous cell carcinoma of the lung.
Monday, February 11, 2013
Oncolytics Meets Primary Endpoint for First Stage of U.S. Phase 2 SCLC Clinical Trial
Primary objective of the trial is to assess the antitumor effect of the treatment regimen.
Friday, February 01, 2013
Oncolytics Completes Patient Enrollment in U.S. Phase I Clinical Trial
Phase I clinical trial investigate REOLYSIN® in combination with FOLFIRI in patients with colorectal cancer.
Monday, August 27, 2012
Oncolytics Announces Second Quarter 2012 Results
Company announces completion of enrollment in the first, 80-patient stage of Phase III clinical trial in head and neck cancers.
Monday, August 06, 2012
Oncolytics Enters into Sponsorship Agreement with NCIC CTG
Agreement for randomized phase II study in advanced and metastatic breast cancers.
Friday, June 22, 2012
Scientific News
Gene Therapy for Metabolic Liver Diseases
Researchers have tested gene therapy in pigs from hereditary tyrosinemia type 1, with corrected liver cells being transplanted into the diseased liver.
Gene Terapy for Muscle Wasting Developed
New gene therapy could save millions of people suffering from muscle wasting disease.
Gene-Editing 'Toolbox' Targets Multiple Genes Simultaneously
Researchers have designed a system that modifies, or edits, multiple genes in a genome at once while minimising unintentional effects.
Discovering the First Farmers
Genetic analyses reveal a collection of highly distinct groups in the Near East and Europe at the dawn of agriculture.
Fighting Cancer Through Protein Pathways
Researchers have found a new drug target within a protein production pathway critical to regulating growth and proliferation of cells.
Mutations in DNA-Repair Genes Found in Advanced Prostate Cancers
New findings indicate that nearly 12% of male advanced prostate cancer sufferers have inherited mutation in DNA-repair genes.
Ice Bucket Challenge Instrumental in Gene Discovery
Donations from the ALS Ice Bucket Chellenge allowed for the largest-ever study of inherited ALS, which identified a new ALS gene.
Triple-Action Therapy Patch Shows Promise
Patch that delivers drug, gene, and light-based therapy to tumor sites shows promising results in mice.
Cancer Gene-Drug Combinations Ripe for Precision Medicine
The study aims to expand the number of cancer gene mutations that can be paired with a precision therapy.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!